ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry.
Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pharmacovigilance signals of dupilumab among pediatric patients: A real‑world analysis based on the FAERS database.Human vaccines & immunotherapeutics · 2026Article
- Dupilumab's Real-World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis.The Australasian journal of dermatology · 2026Article
- Association between Dupilumab and Ocular Surface Diseases in Children.Ophthalmology science · 2026Article
- The evaluation of cytokine profiles in atopic dermatitis patients treated with dupilumab: association with ocular complications.Frontiers in immunology · 2026Article
- Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.Allergologie select · 2026Article
- Clinical Outcomes of Dupilumab-Associated Ocular Surface Disease in the Paediatric Population.Cureus · 2025Article
- Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis.Current opinion in allergy and clinical immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupilumab-associated ocular surface disease (DAOSD) is a common side effect in paediatric atopic dermatitis (AD) patients treated with dupilumab. However, long-term real-world safety data is limited. Therefore, this study investigates the incidence of DAOSD in paediatric AD patients treated with dupilumab and identifies associated risk factors.
methodsThis prospective study included paediatric AD patients (aged 3-17 years) treated with dupilumab. Ocular symptoms were assessed every 4-12 weeks. DAOSD was initially treated with lubricating eye drops, antihistamine eye drops, and/or tacrolimus ointment for the external eyelids. Persistent symptoms were treated with ocular anti-inflammatory therapy. Ophthalmological examination was performed in patients with DAOSD requiring ocular anti-inflammatory therapy. Univariable and multivariable regression analyses were conducted to identify predictors for developing DAOSD.
resultsA total of 104 patients (11.7 ± 4.0 years) with a median follow-up of 70.5 weeks were included. Overall, 34.6% (36/104) of patients developed DAOSD, of which 30.6% (11/36) required ocular anti-inflammatory therapy. The development of DAOSD was not age-dependent, nor was it associated with pre-existing allergic conjunctivitis. The most common ocular symptoms were pruritus (75.0%), redness (72.2%), and tearing (58.3%). Ophthalmological examination revealed tarsal conjunctivitis in all patients with DAOSD requiring ocular anti-inflammatory therapy. Baseline serum IgE levels of ≥ 3000 kU/L were independently associated with the development of DAOSD (OR 4.65; 95% CI 1.43-15.11, p = 0.011). DAOSD led to dupilumab discontinuation in 3.8% (4/104) of patients.
conclusionsThis prospective, long-term, real-world study shows that 34.6% of paediatric AD patients treated with dupilumab develop DAOSD. Elevated baseline serum IgE (≥ 3000 kU/L) may predict the development of DAOSD. The high incidence of DAOSD underscores the importance of awareness of ocular symptoms during dupilumab treatment, especially in (young) paediatric patients, where reporting ocular symptoms can be challenging and may lead to delayed diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.